MedTrace Logo

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-08-20

Study results available
· View outcomes & findings →

Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Conditions

  • Depression, Unipolar

Interventions

DRUG

Intravenous Ketamine

Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Sponsors & Collaborators

  • Rebecca Price

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2023-07-15
Completion
2023-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916548 on ClinicalTrials.gov